Arcus Biosciences falls on stock offering launch

Arcus Biosciences

30/10/2025 20:58

** Shares of Arcus Biosciences RCUS.N down 5.7% post-market at $19.05 as co seeks equity raise

    ** Biopharma focused on developing therapies for cancer, inflammatory and autoimmune diseases commences stock offering; deal size not disclosed

** Leerink Partners and Goldman Sachs joint bookrunners

** Hayward, California-based co has about 108 mln shares outstanding for roughly $2 bln market cap

** Stock ended down 0.5% at $20.19 on Thurs, up ~36% YTD

    ** 11 of 13 analysts rate RCUS "strong buy" or "buy", 2 rate "hold"; median PT of $29 up from $25 a month ago, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))